nternational studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a ???sham??? procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the di